FDA updates CAR T-cell therapy labels for liso-cel and ide-cel, easing monitoring requirements and expanding access for ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued ...

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in ...

SGR-1505 was designed using Schrödinger's computational platform at scale and was discovered approximately 10 months after the company started its MALT1 program. A Phase 1 study in patients with ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Panelists discuss the future of Bruton tyrosine kinase (BTK) inhibitor therapies, considering emerging treatments, regulatory changes, evolving cost dynamics, and the current unmet needs in chronic ...

Arnold Clark has donated £30,000 to a customer towards a new car thanks to her fundraising efforts in this year’s Glasgow ...

JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.

Johnson & Johnson offers stability with 62 years of dividend growth and a 3.44% yield. Click for why JNJ is undervalued and ...

Fiona Slicer walked the Glasgow Kiltwalk in honour of her mum who is battling cancer - landing herself a £30k car prize.

T cell therapy, zilovertamab vedotin in relapsed or refractory (R/R) LBCL, and optimal dosing of AFM13 plus AlloNK in R/R ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...